Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rovelizumab (ICOS Corp).

R Jones1

  • 1Trinity Cottage, Killiney Hill Road, Killiney, Co Dublin, Ireland, rjj101@excite.com

Idrugs : the Investigational Drugs Journal
|August 16, 2005
PubMed
Summary
This summary is machine-generated.

Rovelizumab, a monoclonal antibody, was found to be safe but did not show clinical benefit in multiple sclerosis exacerbations. Further trials investigated its potential in myocardial infarction and stroke, with preclinical studies showing neuroprotective effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrastructural analysis of contractile cell development in lung microvessels in hyperoxic pulmonary hypertension. Fibroblasts and intermediate cells selectively reorganize nonmuscular segments.

The American journal of pathology·1992
Same author

ACP Broadsheet No 134: December 1992. How to harvest bone marrow for transplantation.

Journal of clinical pathology·1992
Same author

Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor.

Biochimica et biophysica acta·1992
Same author

Eating habits and eating disorders during pregnancy.

Psychosomatic medicine·1992
Same author

Effect of radiation dose on the development of mixed haemopoietic chimerism following T cell-depleted allogeneic bone marrow transplantation.

Bone marrow transplantation·1992
Same author

Reasons for consultation in irritable bowel syndrome: symptoms and patient characteristics.

The British journal of general practice : the journal of the Royal College of General Practitioners·1992
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Immunology
  • Neurology
  • Cardiology

Background:

  • Rovelizumab is a humanized monoclonal antibody targeting leukointegrin receptors.
  • It is being investigated for multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI), and stroke.

Purpose of the Study:

  • To evaluate the safety and efficacy of rovelizumab in patients with acute exacerbations of MS.
  • To assess rovelizumab's safety, pharmacokinetics, and infarct size in MI patients.
  • To investigate rovelizumab's efficacy in acute ischemic stroke and trauma-induced hemorrhagic shock.

Main Methods:

  • Phase II and III clinical trials involving placebo-controlled, randomized, double-blind designs.
  • Preclinical studies in rabbit models of focal ischemia.
  • Evaluation of safety, efficacy, pharmacokinetics, and infarct size.

Related Experiment Videos

Main Results:

  • Rovelizumab demonstrated safety in MS patients but no significant clinical benefit for neurological recovery.
  • No significant difference in adverse events or immunogenicity was observed in stroke patients.
  • Preclinical studies showed significant neuroprotection and reduced neutrophil infiltration in ischemic brain tissue.

Conclusions:

  • Rovelizumab is safe but ineffective for acute MS exacerbations.
  • Further research is warranted for its potential in cardiovascular and cerebrovascular conditions.
  • Rovelizumab's mechanism of blocking neutrophil adhesion shows promise in preclinical models of ischemia.